Compare TWLO & PODD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TWLO | PODD |
|---|---|---|
| Founded | 2008 | 2000 |
| Country | United States | United States |
| Employees | 5587 | N/A |
| Industry | Computer Software: Prepackaged Software | Medical/Dental Instruments |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 18.9B | 17.0B |
| IPO Year | N/A | 2007 |
| Metric | TWLO | PODD |
|---|---|---|
| Price | $126.30 | $228.80 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 25 | 20 |
| Target Price | $143.00 | ★ $357.65 |
| AVG Volume (30 Days) | ★ 1.8M | 1.0M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 3.48 |
| Revenue | N/A | ★ $2,708,100,000.00 |
| Revenue This Year | $14.24 | $24.33 |
| Revenue Next Year | $8.38 | $19.33 |
| P/E Ratio | $526.76 | ★ $63.05 |
| Revenue Growth | N/A | ★ 30.73 |
| 52 Week Low | $77.51 | $216.49 |
| 52 Week High | $145.90 | $354.88 |
| Indicator | TWLO | PODD |
|---|---|---|
| Relative Strength Index (RSI) | 57.75 | 36.15 |
| Support Level | $113.82 | N/A |
| Resistance Level | $135.90 | $299.75 |
| Average True Range (ATR) | 4.54 | 6.98 |
| MACD | 0.91 | -0.84 |
| Stochastic Oscillator | 78.28 | 31.28 |
Twilio is a cloud-based communications platform-as-a-service company offering communication building blocks that allow for a fully customized customer engagement experience spanning voice, video, chat, and SMS messaging. It does this through various application programming interfaces and prebuilt solution applications aimed at improving customer engagement. The company leverages its Super Network, a global network of carrier relationships, to facilitate high-speed, cost-effective communication.
Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the US Food and Drug Administration in 2005, approximately 500,000 insulin-dependent diabetic patients are using it worldwide.